%0 Journal Article
%T 肺癌骨转移的分子机制及其治疗进展<br>Molecular Mechanism and Treatment Progress of Bone Metastasis of Lung Cancer
%A 李金龙
%J World Journal of Cancer Research
%P 79-84
%@ 2164-9057
%D 2023
%I Hans Publishing
%R 10.12677/WJCR.2023.132012
%X 肺癌是当今世界死亡率最高的癌症，癌症晚期引起的骨转移是癌性疼痛的主要原因之一，严重影响患者的预后。非小细胞肺癌(NSCLC)患者在病程中发生骨转移占有超过50%的病例。这种转移部位可导致骨骼相关事件(SRE)的发生，例如严重疼痛，病理性骨折，脊柱压迫性损失和高钙血症，严重影响患者的生活质量。肺癌骨转移起病晚，表现不明显，且治疗效果差，并且人们对其发病的原因了解浅薄。最近，由于免疫疗法的出现，晚期NSCLC的治疗发生了根本性的变化。单独使用免疫检查点抑制剂(ICI)或与化疗联合使用已成为无驱动基因突变的晚期或转移性NSCLC的主要治疗策略。由于生存率提高，治疗骨转移以及预防SRE变得更加重要。<br />
Lung cancer is the most deadly cancer in the world today. Bone metastasis caused by advanced cancer is one of the main causes of cancer pain, which seriously affects the prognosis of patients. More than 50% of patients with non-small cell lung cancer (NSCLC) have bone metastasis during the disease. This transfer site can lead to the development of skeletal related events (SRE), such as severe pain, pathological fracture, spinal compression loss and hypercalcemia, which seriously affect the quality of life of patients. The bone metastasis of lung cancer starts late, has no obvious manifestation, and treatment effect is poor, and people have little understanding of the cause of its occurrence. Recently, due to the emergence of immunotherapy, the treatment of advanced NSCLC has undergone fundamental changes. The use of immune checkpoint inhibitor (ICI) alone or in combination with chemotherapy has become the main treatment strategy for advanced or metastatic NSCLC without driver gene mutation. Due to the improvement of survival rate, it is more important to treat bone metastasis and prevent SRE.
%K 肺癌，骨转移，分子机制<br>Lung Cancer
%K Bone Metastasis
%K Molecular Mechanism
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=64486